Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

2.

Analysis of Diagnoses Associated with Multiple Sclerosis-Related In-Hospital Mortality Using the Premier Hospital Database.

Ernst FR, Pocoski J, Cutter G, Kaufman DW, Pleimes D.

Int J MS Care. 2016 May-Jun;18(3):154-61. doi: 10.7224/1537-2073.2014-109.

3.

Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S.

Kaufman DW, Reshef S, Golub HL, Peucker M, Corwin MJ, Goodin DS, Knappertz V, Pleimes D, Cutter G.

Mult Scler Relat Disord. 2014 May;3(3):364-71. doi: 10.1016/j.msard.2013.12.003. Epub 2013 Dec 25.

PMID:
25876474
4.

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl C.

Ann Clin Transl Neurol. 2014 Aug;1(8):605-17. doi: 10.1002/acn3.91. Epub 2014 Aug 22.

5.

Causes of death among commercially insured multiple sclerosis patients in the United States.

Goodin DS, Corwin M, Kaufman D, Golub H, Reshef S, Rametta MJ, Knappertz V, Cutter G, Pleimes D.

PLoS One. 2014 Aug 21;9(8):e105207. doi: 10.1371/journal.pone.0105207. eCollection 2014.

6.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C.

JAMA Neurol. 2014 Mar;71(3):306-14. doi: 10.1001/jamaneurol.2013.5993.

7.

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D; BENEFIT Study Group.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9. doi: 10.1136/jnnp-2013-306222. Epub 2013 Nov 11.

8.

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.

Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D, Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH, Sandbrink R, Barkhof F.

Mult Scler. 2014 Feb;20(2):234-42. doi: 10.1177/1352458513494491. Epub 2013 Jul 10.

PMID:
23842212
9.

Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.

Pan F, Goh JW, Cutter G, Su W, Pleimes D, Wang C.

Clin Ther. 2012 Sep;34(9):1966-76. doi: 10.1016/j.clinthera.2012.07.010. Epub 2012 Aug 18.

PMID:
22906738
10.

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.

Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink R.

Mult Scler. 2012 Oct;18(10):1466-71. Epub 2012 Apr 4.

11.

Analysis and evaluation of environmental tobacco smoke exposure as a risk factor for chronic cough.

Groneberg-Kloft B, Feleszko W, Dinh QT, van Mark A, Brinkmann E, Pleimes D, Fischer A.

Cough. 2007 May 2;3:6.

12.

[COPD--chronic obstructive pulmonary disease and its implications for the human organism].

Groneberg DA, Pleimes D, Golpon H, Welte T.

Versicherungsmedizin. 2006 Sep 1;58(3):116-9. Review. German.

PMID:
17002174
13.

Substance P mediates AP-1 induction in A549 cells via reactive oxygen species.

Springer J, Pleimes D, Scholz FR, Fischer A.

Regul Pept. 2005 Jan 15;124(1-3):99-103.

PMID:
15544846

Supplemental Content

Loading ...
Support Center